A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment. The current study, undertaken in 27 patients with gastrointestinal tumours, aimed to assess the toxicity and potential for significant pharmacokinetic interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361914/
https://www.ncbi.nlm.nih.gov/pubmed/15756252
http://dx.doi.org/10.1038/sj.bjc.6602354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361914/
https://www.ncbi.nlm.nih.gov/pubmed/15756252
http://dx.doi.org/10.1038/sj.bjc.6602354

Ejemplares similares